[Contribution of specific immunoglobulin anti-D to prophylaxis of haemolytic disease of the newborn].

Rev Fr Gynecol Obstet

Clinica de Obstetrica si Gynecologie Filantropia, Bulevardul 1 mai 11-13, Sectorul 8, Bucaresti, Roumanie.

Published: October 1973

Specific immunoglobulin anti-D has been used since 1969 at the Filantropia Obstetrical and Gynaecological Clinic in Bucharest. Administration is carried out by the intramuscular route, each ampoule containing 200 microg of specific immunoglobulin anti-D. Of 1,164 observations, 445 mothers had received the treatment. 425 of whom were treated at the time of the birth of their first child and 4 after an abortion. 16 other cases were women treated at the time of a second birth. The therapy was at first limited to primiparas but has now been extended to multiparas and to patients presenting with abortions, ectotropic pregnancies or retention of dead ova. when it was possible that the child would have been Rh positive. The Kleihauer test has been abandoned except in cases where considerable blood transfer could occur between the fetus and the mother, justifying an increase in the therapeutic doses. The results appear to be extremely satisfactory.

Download full-text PDF

Source

Publication Analysis

Top Keywords

specific immunoglobulin
12
immunoglobulin anti-d
12
treated time
8
[contribution specific
4
anti-d prophylaxis
4
prophylaxis haemolytic
4
haemolytic disease
4
disease newborn]
4
newborn] specific
4
anti-d 1969
4

Similar Publications

Background And Objectives: Breast cancers (BCs) of patients with paraneoplastic neurologic syndromes and anti-Yo antibodies (Yo-PNS) overexpress human epidermal growth factor receptor 2 (HER2) and display genetic alterations and overexpression of the Yo-onconeural antigens. They are infiltrated by an unusual proportion of B cells. We investigated whether these features were also observed in patients with PNS and anti-Ri antibodies (Ri-PNS).

View Article and Find Full Text PDF

Conformational Antibodies to Proteolipid Protein-1 and Its Peripheral Isoform DM20 in Patients With CNS Autoimmune Demyelinating Disorders.

Neurol Neuroimmunol Neuroinflamm

March 2025

Neuroimmunology Laboratory and Neuroimmunology Research Section, IRCCS Mondino Foundation, Pavia, Italy.

Background And Objectives: Antibodies to proteolipid protein-1 (PLP1-IgG), a major central myelin protein also expressed in the peripheral nervous system (PNS) as the isoform DM20, have been previously identified mostly in patients with multiple sclerosis (MS), with unclear clinical implications. However, most studies relied on nonconformational immunoassays and included few patients with non-MS CNS autoimmune demyelinating disorders (ADDs). We aimed to investigate conformational PLP1-IgG in the whole ADD spectrum.

View Article and Find Full Text PDF

Antibody-drug conjugates (ADCs) hold promise to advance targeted therapy of pancreatic ductal adenocarcinoma (PDAC), where the desmoplastic tumor stroma challenges effective treatment. Here, we explored the urokinase plasminogen activator receptor (uPAR) as a candidate ADC target in PDAC, harnessing its massive tumoral and stromal expression in this stroma-dense tumor. We generated a site-specific ADC offering high-affinity, cross-species reactivity, and efficient internalization of the anti-uPAR monoclonal antibody, FL1, carrying a potent anthracycline derivative (PNU-158692).

View Article and Find Full Text PDF

Background: Examples of group B red cells that react weakly or not at all with anti-B have been described. Subgroups of B such as B, B, B, and B are rare and are less frequently reported. We studied the frequency of subgroups of B in our healthy blood donor population and serologically characterized and differentiated these subgroups.

View Article and Find Full Text PDF

Objective: To identify independent risk factors for Henoch-Schönlein purpura nephritis (HSPN) in pediatric patients.

Methods: This study enrolled 180 pediatric patients (90 with HSP, 90 with HSPN) hospitalized at the 940th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army from December 2022 to October 2023, with a follow-up of at least six months. Clinical data were collected at the time of the first onset of HSP.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!